Saturday 17 October 2026
Export APYX’s income statement to Excel — free account
Apyx Medical Corporation
APYX Healthcare Medical Devices
Apyx Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.8 million, up 9.86% from fiscal 2024. In the quarter to June 2026, revenue grew 22.1%, EPS grew 22.2%, free cash flow fell 137.4% and total debt rose 2.74%, each against the same quarter a year earlier.
2.55
0.01
−0.39%
Follow APYX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 4 | 3 | 4 | 4 | 2 | 4 | 2 | 4 |
P/E ratio |
3.37 | 3.37 | 3.37 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
13.06 | 13.06 | 13.06 | 10.21 | 8.89 | 9.07 | 1.95 | 1.77 | 1.17 | 2.72 |
Altman Z-Score |
— | — | — | 13.50 | 14.87 | 18.54 | 2.58 | 0.89 | (0.39) | 1.10 |
Altman Z″-Score (non-manufacturers) |
2.72 | 0.08 | 16.18 | 9.44 | 9.87 | 6.38 | 1.47 | 1.61 | (0.95) | (0.11) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 62.25 | 0.00 | 0.00 |
Beneish M-Score |
(0.79) | (3.99) | (1.86) | (0.35) | (1.30) | (2.58) | (2.57) | (3.48) | (2.72) | (2.63) |
P/Operating CF |
(12.08) | (12.08) | (12.08) | (88.66) | (242.21) | 2,056.71 | (19.20) | (41.79) | (19.12) | (56.85) |
P/B ratio |
2.50 | 2.50 | 2.50 | 4.04 | 3.86 | 8.15 | 2.30 | 3.43 | 3.92 | 9.70 |
Price to Tangible BV |
2.51 | 2.51 | 2.51 | 4.06 | 3.87 | 8.18 | 2.31 | 3.46 | 3.97 | 9.82 |
EV/Sales |
8.38 | 8.38 | 8.38 | 8.16 | 7.40 | 8.44 | 1.73 | 1.74 | 1.40 | 2.95 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(6.70) | (6.70) | (6.70) | (12.47) | (12.76) | (39.20) | (3.80) | (17.32) | (3.73) | (19.48) |
EV/FCF |
(6.58) | (6.58) | (6.58) | (11.65) | (12.31) | (36.66) | (3.62) | 61.22 | (3.58) | (17.10) |
Quick Ratio |
3.79 | 2.60 | 9.68 | 5.56 | 6.47 | 3.94 | 2.40 | 4.53 | 4.40 | 4.15 |
Current Ratio |
5.03 | 3.77 | 10.43 | 6.23 | 7.22 | 4.60 | 3.63 | 5.52 | 5.26 | 5.00 |
Net Debt/EBITDA |
1.16 | 0.61 | 5.74 | 2.90 | 2.17 | 2.28 | 0.45 | 0.63 | (0.12) | (0.54) |
Debt/Assets |
8.07% | 8.37% | 0.15% | 0.50% | 0.25% | 0.03% | 0.14% | 41.95% | 52.32% | 52.16% |
Debt/Equity |
0.11 | 0.12 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 1.23 | 2.37 | 2.35 |
Asset Turnover |
0.27 | 0.31 | 0.26 | 0.31 | 0.35 | 0.68 | 0.74 | 0.80 | 0.67 | 0.80 |
Operating CF/Net income |
0.72 | 0.73 | (0.33) | 0.94 | 1.35 | 0.69 | 0.87 | 0.28 | 0.77 | 0.71 |
Capex/Depreciation |
(0.39) | (0.90) | (0.54) | (1.73) | (0.65) | (0.80) | (1.13) | 9.73 | (1.21) | (1.70) |
Interest Coverage |
(72.10) | (102.10) | (137.27) | (2,608.62) | (436.59) | (1,444.80) | (1,570.80) | (6.96) | (3.19) | (1.15) |
| (15.92%) | (20.98%) | 114.86% | (24.88%) | (17.61%) | (25.74%) | (50.51%) | (57.83%) | (113.74%) | (76.88%) | |
| (11.87%) | (15.32%) | 98.84% | (21.81%) | (14.98%) | (21.24%) | (38.48%) | (28.57%) | (32.57%) | (17.03%) | |
ROIC |
(51.51%) | (62.17%) | (98.67%) | (101.36%) | (56.73%) | (38.99%) | (53.21%) | (65.34%) | (71.30%) | (22.44%) |
Return on Tangible Assets |
(14.25%) | (22.39%) | 72.08% | (27.74%) | (18.74%) | (28.04%) | (61.20%) | (31.43%) | (49.18%) | (22.81%) |
Average Days of Receivables |
195.89 | 173.23 | 111.67 | 124.70 | 228.24 | 159.21 | 149.62 | 97.77 | 117.46 | 115.87 |
Research and Development Expense of Revenue |
11.71% | 18.97% | 15.35% | 13.21% | 14.15% | 8.91% | 10.21% | 10.39% | 10.56% | 6.38% |
Selling, General and Administrative Expense of Revenue |
175.47% | 184.70% | 135.82% | 128.32% | 121.49% | 90.13% | 108.18% | 92.21% | 89.65% | 68.35% |
Intangible Assets out of Total Assets |
0.05 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
9.17% | 8.51% | 13.39% | 12.68% | 15.19% | 10.49% | 15.05% | 9.77% | 8.34% | 3.79% |
Graham Net Nets |
0.37 | 0.37 | 0.37 | 0.22 | 0.23 | 0.10 | 0.33 | 0.20 | 0.11 | 0.04 |
Graham Number |
0.00 | 0.00 | 10.57 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
29.68% | 29.68% | 29.68% | (6.62%) | (4.86%) | (3.43%) | (26.59%) | (20.22%) | (42.41%) | (7.71%) |
Free Cash Flow Yield |
(9.74%) | (9.74%) | (9.74%) | (6.86%) | (6.76%) | (2.54%) | (24.48%) | 1.61% | (33.42%) | (6.34%) |
Revenue per Share |
0.32 | 0.33 | 0.50 | 0.83 | 0.81 | 1.41 | 1.29 | 1.51 | 1.35 | 1.29 |
Operating CF per Share |
(0.10) | (0.12) | (0.63) | (0.54) | (0.47) | (0.30) | (0.59) | (0.15) | (0.51) | (0.19) |
Capex per Share |
(0.01) | (0.02) | (0.01) | (0.04) | (0.02) | (0.02) | (0.03) | 0.19 | (0.02) | (0.03) |
Free Cash Flow per Share |
(0.11) | (0.14) | (0.64) | (0.58) | (0.49) | (0.33) | (0.62) | 0.04 | (0.53) | (0.22) |
Cash per Share |
0.56 | 0.34 | 2.36 | 1.73 | 1.23 | 0.90 | 0.30 | 1.26 | 0.89 | 0.77 |
Shareholders Equity per Share |
0.96 | 0.70 | 2.63 | 2.09 | 1.87 | 1.57 | 1.09 | 0.78 | 0.40 | 0.36 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.96 | 0.70 | 2.63 | 2.09 | 1.87 | 1.57 | 1.09 | 0.78 | 0.40 | 0.36 |
Free Cash Flow |
(3.12) | (4.33) | (21.24) | (19.78) | (16.65) | (11.17) | (21.29) | 1.49 | (18.77) | (9.11) |
Working Capital |
21.27 | 16.57 | 81.22 | 64.42 | 56.94 | 47.53 | 31.12 | 57.62 | 45.72 | 46.77 |
Capital Expenditures |
(0.29) | (0.62) | (0.36) | (1.30) | (0.58) | (0.72) | (1.01) | 6.73 | (0.72) | (1.11) |
Net Current Asset Value |
17.65 | 13.59 | 81.08 | 63.25 | 55.84 | 46.03 | 28.99 | 18.04 | 5.93 | 6.46 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.06 | 0.02 | 0.05 | 0.02 | 0.01 | 0.02 | (0.13) | 0.02 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.11 | 0.12 | 0.12 | 0.11 | 0.14 | 0.14 | 0.13 | 0.36 | 0.30 | 0.28 |
Cash ROIC |
(7.05%) | (12.26%) | (12.83%) | (15.15%) | (15.71%) | (13.16%) | (44.30%) | 1.43% | (23.46%) | (11.19%) |
Accounts Receivable Turnover |
2.30 | 2.13 | 3.34 | 3.83 | 2.05 | 2.52 | 2.26 | 3.24 | 3.26 | 3.28 |
Accounts Payable Turnover |
2.63 | 2.05 | 3.85 | 4.74 | 5.17 | 7.20 | 5.80 | 6.91 | 7.04 | 6.98 |
Inventory Turnover |
0.61 | 0.63 | 1.56 | 2.23 | 2.24 | 2.75 | 1.66 | 1.71 | 2.14 | 2.45 |
Average Days of Payables |
158.30 | 176.37 | 89.88 | 97.35 | 54.03 | 64.38 | 63.35 | 53.25 | 50.93 | 56.37 |
Days of Inventory on Hand |
606.99 | 476.19 | 198.70 | 202.37 | 144.86 | 165.86 | 279.99 | 194.83 | 147.31 | 158.57 |
Average Receivables |
3.83 | 4.80 | 4.97 | 7.36 | 13.49 | 19.25 | 19.70 | 16.13 | 14.75 | 16.13 |
Average Payables |
1.41 | 1.59 | 1.50 | 1.93 | 1.97 | 2.07 | 2.65 | 2.69 | 2.66 | 2.84 |
Average Inventory |
6.06 | 5.22 | 3.71 | 4.11 | 4.56 | 5.41 | 9.29 | 10.86 | 8.74 | 8.08 |
Average Assets |
33.28 | 33.05 | 63.46 | 90.34 | 79.43 | 71.42 | 60.25 | 65.51 | 72.04 | 65.84 |
Average Common Equity |
24.81 | 24.13 | 54.60 | 79.22 | 67.56 | 58.93 | 45.90 | 32.36 | 20.63 | 14.58 |
Columns are period end dates